T. V. van Duijl

发表

Longitudinal nonlinear mixed effects modeling of EGFR mutations in ctDNA as predictor of disease progression in treatment of EGFR‐mutant non‐small cell lung cancer

J. Beijnen, A. Huitema, D. van den Broek, 2022, Clinical and translational science.

Reference intervals of urinary kidney injury biomarkers for middle-aged men and women determined by quantitative protein mass spectrometry

R. de Mutsert, F. Rosendaal, J. D. de Fijter, 2022, Annals of clinical biochemistry.

Kidney Injury Biomarkers in an Academic Hospital Setting: Where Are We Now?

J. D. de Fijter, C. Cobbaert, L. Ruhaak, 2019, The Clinical biochemist. Reviews.

Equilibrium and kinetic selectivity profiling on the human adenosine receptors.

A. IJzerman, D. Guo, L. Heitman, 2016, Biochemical pharmacology.

A binding kinetics study of human adenosine A3 receptor agonists

K. Jacobson, A. IJzerman, L. Heitman, 2018, Biochemical pharmacology.

Monitoring of EGFR mutations in circulating tumor DNA of non-small cell lung cancer patients treated with EGFR inhibitors

J. Schellens, J. Beijnen, A. Huitema, 2021, Cancer Chemotherapy and Pharmacology.

Rational selection of a biomarker panel targeting unmet clinical needs in kidney injury

J. D. de Fijter, C. Cobbaert, L. Ruhaak, 2021, Clinical proteomics.

Structure–Affinity Relationships and Structure–Kinetics Relationships of Pyrido[2,1-f]purine-2,4-dione Derivatives as Human Adenosine A3 Receptor Antagonists

A. IJzerman, L. Heitman, J. V. van Veldhoven, 2017, Journal of medicinal chemistry.

Urinary Kidney Injury Biomarkers Are Associated with Ischemia-Reperfusion Injury Severity in Kidney Allograft Recipients.

J. D. de Fijter, S. le Cessie, F. Romijn, 2023, Clinical chemistry.